Sutter Health Research Enterprise
701 E. El Camino Real
North Wing, 1st Floor
Mountain View, CA, 94040
(650) 934-7600
taie1@pamf.org
Primary Research Interests
Related Clinical Trials
Adjuvant (AFT-19)
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Investigators: Priya Chakravarthi M.D., M. Dwight Chen M.D., Natalia Colocci M.D., Ph.D., Huan T. Ha M.D., Gillian L. Hsieh M.D., Paula D. Kushlan M.D., David S. Leibowitz M.D., FACP, Kim-Son Nguyen M.D., Albert Pisani M.D., Bryant C. Sheh M.D., Edmund W. Tai M.D., Janet Wang M.D., Derrick Wong M.D., Glenn D. Wong D.O., Irene Wu M.D., Michael C. Wu M.D., Monique de Bruin M.D., MPH
Status: Active, Recruiting
Adjuvant (Alliance A081801)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Investigator: Edmund W. Tai M.D.
Status: Active, Recruiting
Adjuvant (Alliance A151216) ALCHEMIST Screening Trial
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Investigator: Edmund W. Tai M.D.
Status: Active, Recruiting
Adjuvant (ECOG E4512)
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment)
Investigator: Edmund W. Tai M.D.
Status: Active, Recruiting
Adjuvant (SWOG S1806)
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Investigator: Edmund W. Tai M.D.
Status: Active, Recruiting
Adjuvant Merkel Cell (ECOG-ACRIN EA6174)
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
Investigator: Edmund W. Tai M.D.
Status: Active, Recruiting